Format

Send to

Choose Destination
Pigment Cell Melanoma Res. 2009 Aug;22(4):454-60. doi: 10.1111/j.1755-148X.2009.00576.x. Epub 2009 Apr 29.

Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Author information

1
Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV, USA.

Abstract

While many genetic alterations have been identified in melanoma, the relevant molecular events that contribute to disease progression are poorly understood. Most primary human melanomas exhibit loss of expression of the CDKN2A locus in addition to activation of the canonical mitogen-activated protein kinase signaling pathway. In this study, we used a Cdkn2a-deficient mouse melanocyte cell line to screen for secondary genetic events in melanoma tumor progression. Upon investigation, intrachromosomal gene amplification of Met, a receptor tyrosine kinase implicated in melanoma progression, was identified in Cdkn2a-deficient tumors. RNA interference targeting Met in these tumor cells resulted in a significant delay in tumor growth in vivo compared with the control cells. MET expression is rarely detected in primary human melanoma but is frequently observed in metastatic disease. This study validates a role for Met activation in melanoma tumor progression in the context of Cdkn2a deficiency.

PMID:
19422607
PMCID:
PMC2775091
DOI:
10.1111/j.1755-148X.2009.00576.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center